Real Stories.
Enhance your knowledge about heart failure treatment through this series of real world cases. Each case highlights a different aspect in HF management and can help you take better decisions for your patients.
![](/sites/medhub.novartis.co.in/files/De%20novo%20ADHF_compendium%20booklet%20with%20DC_19%20Oct%2022_Page_1_0.jpg)
De novo acute decompensated heart failure
Explore a real de novo ADHF case and understand how the introduction of GDMT like sacubitril/valsartan during hospitalization can help reduce the risk of mortality and rehospitalization.
![](/sites/medhub.novartis.co.in/files/Worsening%20HF_compendium%20booklet%20with%20DC_2%20Nov%2022-1_0.jpg)
Worsening heart failure symptoms
Worsening heart failure is associated with high risk of adverse outcomes. This real case can help you understand the role of sacubitril/valsartan in reducing HF symptoms, thereby lowering the risk of CV death and all-cause mortality.
![](/sites/medhub.novartis.co.in/files/Feb_visit%204_Early%20diagnosis%20booklet_3%20Jan%2023-1%20copy.jpg)
Early diagnosis of heart failure
About 80% heart failure patients remain undiagnosed. This real case helps you understand how early diagnosis can offer an opportunity to prescribe effective pharmacological interventions like sacubitril/valsartan that may delay HF progression.
![](/sites/medhub.novartis.co.in/files/March_Visit%204_History%20of%20hospitalization_Booklet_3%20Jan%2023-1%20copy.jpg)
History of hospitalization: Increased vulnerability in patients with heart failure
In patients with heart failure, the post-discharge period is often called the ‘vulnerable phase’. This real case highlights how the optimal use of sacubitril/valsartan can help improve outcomes after discharge.
![](/sites/medhub.novartis.co.in/files/Visit%204_April_Diabetes%20mellitus_booklet_21%20Mar%202023_Page_1_1.jpg)
Diabetes Mellitus: Not just a bystander with HF
Patients with DM have over twice the risk of developing HF than patients without DM. This real case throws light on improved outcomes with sacubitril/valsartan in a high-risk population.
![](/sites/medhub.novartis.co.in/files/Visit_4_May_HF_and_DCM_Booklet_30_March_2023_Page_1.jpg)
Heart failure and Dilated Cardiomyopathy
This real case helps you understand how sacubitril/valsartan improves QoL, NYHA functional class and 6-MWT, ECHO parameters, and reduces the risk of CV death or hospitalisation in patients with HF & DCM.
![](/sites/medhub.novartis.co.in/files/Visit_4_May_HF_and_DCM_Booklet_30_March_2023_Page_22_Page_1.jpg)
The plethora of co-morbidities with HF
The presence of co-morbidities in HF is associated with a poor prognosis. This case explains the importance of implementing the right therapy to reduce mortality in HFrEF patients with co-morbidities.
![](/sites/medhub.novartis.co.in/files/Edition_08_Renal_dysfunction_with_HF_Booklet_29_March_2023_Page_1.jpg)
Renal dysfunction with HF
This real case can help you understand how to implement therapy at the right dose to improve survival and reduce hospitalization in HFrEF patients with WRF.
![](/sites/medhub.novartis.co.in/files/Edition_09_HF_and_hypertension_booklet_29_March_2023_Page_1.jpg)
Heart failure and Hypertension
Hypertension is a major risk factor for the incidence and progression of HF. This case highlights the role of sacubitril/valsartan to reduce the risk of CV death and hospitalization.
![](/sites/medhub.novartis.co.in/files/Edition_10_Mitral_regurgitation_in_HF_booklet_29_March_2023_Page_1.jpg)
Managing Mitral Regurgitation in HF
Explore a case of FMR in HF and understand how GDMT like sacubitril/valsartan improves LVEF and reduces regurgitant volume, ESV, EDV and EDVI.